Inherited muscular disorders such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) are progressive genetic diseases for which curative treatments remain elusive. Recent advances in biotechnology have brought antibody-based therapies into focus as precision tools to enhance drug delivery, modulate inflammation, and extend functional benefits. This article explores the mechanisms by which antibodies contribute to current and emerging therapeutic strategies for these disorders.
Inherited muscular disorders encompass a heterogeneous group of genetic conditions characterized by progressive skeletal muscle degeneration. Common subtypes include Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Myotonic Dystrophy Type 1 (DM1), and congenital muscular dystrophies. While these diseases differ in onset, severity, and genetic mutations, they share challenges in drug delivery, tissue targeting, and immune tolerance. Antibodies have emerged as key molecular tools in overcoming these obstacles.
Antibody-oligonucleotide conjugates are engineered molecules that fuse antisense oligonucleotides (ASOs) with antibodies targeting muscle-specific receptors, most notably transferrin receptor 1 (TfR1). This strategy enables:
Improved cellular uptake in skeletal, cardiac, and smooth muscle tissues
Enhanced endosomal escape, allowing therapeutic oligonucleotides to reach their nuclear targets
Tissue-specific biodistribution, minimizing off-target effects
Two leading examples:
DYNE-101 (Dyne Therapeutics): targets DMPK RNA in DM1, showing reduction in toxic RNA foci and functional improvement in early-phase trials.
del-zota and AOC 1001 (Avidity Biosciences): applied in DMD and DM1 respectively, with del-zota demonstrating up to 25% dystrophin restoration and significant reduction in muscle damage biomarkers.
In the context of muscular dystrophies, chronic inflammation accelerates muscle degradation. Monoclonal antibodies (mAbs) are being investigated for their ability to:
Neutralize pro-inflammatory cytokines (e.g., TNF-α, IL-6)
Target immune checkpoints or complement pathways contributing to muscle damage
Overcome immune exclusion barriers in gene therapy (e.g., antibodies against AAV capsids in DMD gene therapy candidates)
Additionally, immunomodulatory agents like imlifidase are under investigation to remove pre-existing antibodies to AAV vectors, potentially allowing redosing of gene therapies like Sarepta’s Elevidys.
Capricor Therapeutics’ deramiocel, an allogeneic cardiosphere-derived cell therapy, leverages the regenerative and immunomodulatory effects of donor heart cells. These cells exert:
Anti-fibrotic and anti-inflammatory actions
Potential antibody-mediated regeneration via paracrine signaling
Preservation of cardiac function, a critical determinant of survival in non-ambulatory DMD patients
In trials, deramiocel slowed upper limb and cardiac function decline by nearly 50%, supporting its potential as the first FDA-approved therapy for DMD-related cardiomyopathy.
While antibody-based approaches offer promising solutions, key challenges remain:
Immunogenicity of repeated dosing
Manufacturing complexity of large conjugates and biologics
Variable receptor expression across disease stages and patient populations
Nonetheless, the intersection of antibody engineering, genetic therapy, and muscle biology continues to evolve. With multiple antibody-driven platforms advancing to Phase III trials and anticipated regulatory submissions by 2026, the next few years may mark a paradigm shift in treating inherited muscular disorders.
Antibodies have moved beyond their traditional role in immune defense to become precision therapeutic delivery vehicles and modulators of disease pathology in inherited muscular disorders. Through innovations like AOCs, immunotherapy adjuncts, and regenerative cell therapies, antibodies are reshaping the landscape of neuromuscular disease treatment, thus offering hope for more effective, personalized interventions.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
